NewEdge Advisors LLC Buys 8,262 Shares of GSK plc (NYSE:GSK)

NewEdge Advisors LLC increased its holdings in GSK plc (NYSE:GSK - Free Report) by 11.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 83,515 shares of the pharmaceutical company's stock after acquiring an additional 8,262 shares during the quarter. NewEdge Advisors LLC's holdings in GSK were worth $2,824,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in GSK. Dorsey & Whitney Trust CO LLC lifted its position in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after buying an additional 278 shares during the period. GC Wealth Management RIA LLC grew its holdings in GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after purchasing an additional 353 shares during the period. Jacobi Capital Management LLC grew its holdings in GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock worth $352,000 after purchasing an additional 389 shares during the period. Gladstone Institutional Advisory LLC increased its stake in shares of GSK by 3.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock valued at $413,000 after purchasing an additional 407 shares in the last quarter. Finally, CENTRAL TRUST Co lifted its holdings in shares of GSK by 5.6% during the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock valued at $262,000 after purchasing an additional 414 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

NYSE:GSK traded down $0.09 during mid-day trading on Friday, reaching $37.42. The company's stock had a trading volume of 3,392,146 shares, compared to its average volume of 4,699,589. The firm's fifty day moving average price is $37.48 and its two-hundred day moving average price is $36.05. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The stock has a market cap of $77.20 billion, a P/E ratio of 23.52, a PEG ratio of 1.12 and a beta of 0.56. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, equities analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were paid a $0.3932 dividend. This represents a $1.57 annualized dividend and a dividend yield of 4.20%. The ex-dividend date of this dividend was Friday, February 21st. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is 100.63%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday. BNP Paribas assumed coverage on GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. Finally, Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Eight analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.